低密度脂蛋白胆固醇(Low Density Lipoprotein Cholesterol, LDL-C)是动脉粥样硬化性心血管疾病的致病性危险因素,动脉粥样硬化是心血管死亡的主要原因。因此,降低LDL-C水平是预防心血管疾病的主要目标。主要用他汀类药物降低血浆胆固...
详细信息
低密度脂蛋白胆固醇(Low Density Lipoprotein Cholesterol, LDL-C)是动脉粥样硬化性心血管疾病的致病性危险因素,动脉粥样硬化是心血管死亡的主要原因。因此,降低LDL-C水平是预防心血管疾病的主要目标。主要用他汀类药物降低血浆胆固醇水平。尽管使用他汀类药物最大剂量治疗,LDL-C降低水平仍不达标,仍存在与血脂相关的心血管风险,各种不良事件增加。目前,研究和开发了几种非他汀类药物,其作用机制与他汀类药物相辅相成,其目的是降低血浆胆固醇水平。Low-density lipoprotein cholesterol (LDL-C) is a pathogenic risk factor for atherosclerotic cardiovascular diseases, which are the leading cause of cardiovascular mortality. Therefore, reducing LDL-C levels is a primary objective in the prevention of cardiovascular diseases. Statin drugs are primarily used to lower plasma cholesterol levels. Despite treatment with the maximum dosage of statin drugs, the reduction in LDL-C levels is still not up to standard, and there is still a cardiovascular risk associated with blood lipids, with an increase in various adverse events. At present, several non-statin drugs have been researched and developed, whose mechanisms of action complement those of statin drugs, with the aim of lowering plasma cholesterol levels.
暂无评论